Clopidogrel (Pharmacogenetics)

Clopidogrel sold under the brand name Plavix is a widely used antiplatelet agent to treat and prevent a variety of atherothrombotic diseases.

Research has implicated genetic variations in the CYP2C19 isozyme as at least partly responsible for the variable antiplatelet response seen with clopidogrel.

Studies have shown that patients possessing genetic variants of the CYP2C19 isozyme may be at increased risk of adverse cardiovascular events due to impaired clopidogrel efficacy, although this has not been definitively demonstrated.